News

June 1, 2001 CSPHP Kyowa SuperSoy is a newly developed soy peptide that significantly decreases serum concentrations of total cholesterol and LDL cholesterol. It was made by fortifying soy's widely known serum-cholesterol reducing property by binding enzymatic-decomposed lecithin to hydrolyzed isolated soy protein in the ration of 80/20 (wt/wt). The two components are considered to be bonded in a hydrophobic manner. Animal Testing: Cross-over tests, using male Wistar rats, indicated that SPHP [fractionated CSPHP] produced the effects of both reducing high cholesterol levels and suppressi...

May 21, 2001 Source: Chemical & Engineering News Japan has a rich tradition of developing materials through fermentation. Large companies such as Kyowa Hakko characterize fermentation as their core business. These companies have traditionally concentrated on food additives and multiclient products, rather than the advanced custom intermediates emphasized by Europe's biocatalysis experts, but a few of Japan's leading firms are now attempting to crack this market as well. For many decades, the Japanese have been impressed by the potential of fermentation processes to produce items othe...

May 1, 2001 NEW YORK, New York - Wacker Biochem Corporation and Kyowa Hakko USA have formed an alliance to market and sell Wacker-produced Cysteine in the United States. Cysteine, one of the twenty amino acids found in living organisms, is used extensively in the pharmaceutical, food and flavor, pet food, nutraceutical and cosmetic industries. The US market is estimated to be in the range of 700 MT per year. Wacker has developed a breakthrough fermentation technology for manufacturing Cysteine. Up to now Cysteine was extracted from ceratine, for instance, from human hair or from chicken f...

March 1, 2001 Kyowa Hakko Introduces CSPHP, Serum Cholesterol Reducing "KyowaSuperSoy" NEW YORK, New York - Kyowa Hakko announced the availability of a new soy peptide food ingredient, KyowaSuperSoy, that significantly reduces serum concentrations of total cholesterol and LDL cholesterol to healthy levels. The new product, CSPHP KyowaSuperSoy, fortifies soy's acknowledged serum-cholesterol reducing properties by binding enzymatic-decomposed lecithin to hydrolyzed isolated soy protein. In clinical trials, patients taking as little as 3 grams of CSPHP KyowaSuperSoy per day saw their high ...

August 1, 2000 NEW YORK, N.Y. - Noted physician, author and nutrition authority, Dr. Erika Schwartz, MD, offers valuable insights on Coenzyme Q10 in a recently released, multi-page report. As described, CoQ10 is synthesized in the body from the amino acid Tyrosine, with the help of vitamins and trace minerals. Although it is manufactured by every human body cell, not enough is produced to satisfy our daily needs. Neither can it be supplied adequately by foods such as organ meats, which contain the highest concentrations of CoQ10. Supplementation is the only practical way to fulfill the av...

June 1, 2000 Source: Nutritional Outlook Coenzyme Q10 has emerged as a multi-purpose ingredient, appropriate for use in a variety of products. The largest body of research shows CoQ10 may be beneficial for the heart, as studies have identified CoQ10 deficiency in many heart patients. A study by the University of Texas found that patients being treated for congestive heart failure who took CoQ10 in addition to standard therapy had a 75 percent chance of survival after three years, while those using conventional therapy only experienced a 25 percent survival rate. In Japan, CoQ10 is an appr...

March 1, 2000 NEW YORK, New York - Kyowa Hakko U.S.A., Inc. announced that its West Coast office has been relocated to Aliso Viejo, California. According to Kyowa's General Manager, Donald Blaine, who heads the office, the move comes in response to recent growth and will also facilitate expected future expansion. The new location is 85 Enterprise, Suite 430, Aliso Viejo, CA 92656, telephone 949-425-0707, facsimile 949-425-0708. Kyowa Hakko is among the world's leading producers and marketers of amino acids, nucleic acids, chemical intermediates, and bio-products for the pharmaceutic...

December 1, 1999 NEW YORK, New York - Kyowa Hakko U.S.A., Inc. is offering an eight-page report on an in-depth study of the long-term toxicity of Natural Coenzyme Q10 (derived from fermentation). The information was published in August, 1999 in the Journal of Agriculture and Food Chemistry. Prompted by the growing application of CoQ10 as a dietary supplement, the objective of the subject research was to rigorously test the chronic toxicity in an experimental design following principles for the safety assessment of food additives (FDA, 1982). Over a 52-week period, CoQ10 was administered d...

August 1, 1999 NEW YORK, New York - Kyowa Hakko U.S.A., Inc. has introduced a new reporting system designed to provide customers with comprehensive technical and quality assurance data on the company's broad range of raw materials. Kyowa Hakko's Universal Certificate of Analysis will measure materials performance based on JP, USP, EP, and FCC criteria. For over fifty years, product quality, performance and consistency have been paramount to Kyowa Hakko. The new Universal Certificate of Analysis, incorporating manufacturing specifications and product test results in a concise, uniform form...

October 1, 1999 Source: Supplement Industry Executive Even as the new millennium approaches, another milestone must first be noted: the recent 50th anniversary of nutritional ingredient supplier Kyowa Hakko. Founded by Dr. Benzabro Kato in July of 1949, Kyowa Hakko is one of the world's leading manufacturer of amino acids, nucleic acids, bio-products and fine chemicals for dietary supplement, food and pharmaceutical industries. The company, which has its international headquarters in Tokyo, operates in the U.S. from a main office in New York City, with an additional West Coast office l...